Cargando…

The Therapeutic Potential of FLASH-RT for Pancreatic Cancer

SIMPLE SUMMARY: Ultra-high dose rate radiation, widely nicknamed FLASH-RT, kills tumors without significantly damaging nearby normal tissues. This selective sparing of normal tissue by FLASH-RT tissue is called the FLASH effect. This review explores some of the proposed mechanisms of the FLASH effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Okoro, Chidi M., Schüler, Emil, Taniguchi, Cullen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909276/
https://www.ncbi.nlm.nih.gov/pubmed/35267474
http://dx.doi.org/10.3390/cancers14051167
_version_ 1784666100431060992
author Okoro, Chidi M.
Schüler, Emil
Taniguchi, Cullen M.
author_facet Okoro, Chidi M.
Schüler, Emil
Taniguchi, Cullen M.
author_sort Okoro, Chidi M.
collection PubMed
description SIMPLE SUMMARY: Ultra-high dose rate radiation, widely nicknamed FLASH-RT, kills tumors without significantly damaging nearby normal tissues. This selective sparing of normal tissue by FLASH-RT tissue is called the FLASH effect. This review explores some of the proposed mechanisms of the FLASH effect and the current data that might support its use in pancreatic cancer. Since radiation for pancreatic cancer treatment is limited by GI toxicity issues and is a disease with one of the lowest five-year survival rates, FLASH-RT could have a large impact in the treatment of this disease with further study. ABSTRACT: Recent preclinical evidence has shown that ionizing radiation given at an ultra-high dose rate (UHDR), also known as FLASH radiation therapy (FLASH-RT), can selectively reduce radiation injury to normal tissue while remaining isoeffective to conventional radiation therapy (CONV-RT) with respect to tumor killing. Unresectable pancreatic cancer is challenging to control without ablative doses of radiation, but this is difficult to achieve without significant gastrointestinal toxicity. In this review article, we explore the propsed mechanisms of FLASH-RT and its tissue-sparing effect, as well as its relevance and suitability for the treatment of pancreatic cancer. We also briefly discuss the challenges with regard to dosimetry, dose rate, and fractionation for using FLASH-RT to treat this disease.
format Online
Article
Text
id pubmed-8909276
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89092762022-03-11 The Therapeutic Potential of FLASH-RT for Pancreatic Cancer Okoro, Chidi M. Schüler, Emil Taniguchi, Cullen M. Cancers (Basel) Review SIMPLE SUMMARY: Ultra-high dose rate radiation, widely nicknamed FLASH-RT, kills tumors without significantly damaging nearby normal tissues. This selective sparing of normal tissue by FLASH-RT tissue is called the FLASH effect. This review explores some of the proposed mechanisms of the FLASH effect and the current data that might support its use in pancreatic cancer. Since radiation for pancreatic cancer treatment is limited by GI toxicity issues and is a disease with one of the lowest five-year survival rates, FLASH-RT could have a large impact in the treatment of this disease with further study. ABSTRACT: Recent preclinical evidence has shown that ionizing radiation given at an ultra-high dose rate (UHDR), also known as FLASH radiation therapy (FLASH-RT), can selectively reduce radiation injury to normal tissue while remaining isoeffective to conventional radiation therapy (CONV-RT) with respect to tumor killing. Unresectable pancreatic cancer is challenging to control without ablative doses of radiation, but this is difficult to achieve without significant gastrointestinal toxicity. In this review article, we explore the propsed mechanisms of FLASH-RT and its tissue-sparing effect, as well as its relevance and suitability for the treatment of pancreatic cancer. We also briefly discuss the challenges with regard to dosimetry, dose rate, and fractionation for using FLASH-RT to treat this disease. MDPI 2022-02-24 /pmc/articles/PMC8909276/ /pubmed/35267474 http://dx.doi.org/10.3390/cancers14051167 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Okoro, Chidi M.
Schüler, Emil
Taniguchi, Cullen M.
The Therapeutic Potential of FLASH-RT for Pancreatic Cancer
title The Therapeutic Potential of FLASH-RT for Pancreatic Cancer
title_full The Therapeutic Potential of FLASH-RT for Pancreatic Cancer
title_fullStr The Therapeutic Potential of FLASH-RT for Pancreatic Cancer
title_full_unstemmed The Therapeutic Potential of FLASH-RT for Pancreatic Cancer
title_short The Therapeutic Potential of FLASH-RT for Pancreatic Cancer
title_sort therapeutic potential of flash-rt for pancreatic cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909276/
https://www.ncbi.nlm.nih.gov/pubmed/35267474
http://dx.doi.org/10.3390/cancers14051167
work_keys_str_mv AT okorochidim thetherapeuticpotentialofflashrtforpancreaticcancer
AT schuleremil thetherapeuticpotentialofflashrtforpancreaticcancer
AT taniguchicullenm thetherapeuticpotentialofflashrtforpancreaticcancer
AT okorochidim therapeuticpotentialofflashrtforpancreaticcancer
AT schuleremil therapeuticpotentialofflashrtforpancreaticcancer
AT taniguchicullenm therapeuticpotentialofflashrtforpancreaticcancer